ホーム > 市場調査レポート > 医薬品 > 神経疾患 > 睡眠障害:プロモーションと認識が市場拡大を促進するか
カテゴリ
医薬品 (4955)
OTC (153)
がん (943)
ドラッグデリバリー (185)
ワクチン (182)
感染症 (351)
規制環境 (130)
後発医薬品 (134)
骨疾患 (37)
処方薬 (157)
神経疾患 (174)
精神疾患 (88)
製薬企業関連 (531)
創薬 (1523)
糖尿病 (192)
動物用医薬 (17)
肥満症 (44)
市場調査レポート

睡眠障害:プロモーションと認識が市場拡大を促進するか

Sleep Disorders: Promotion and Awareness Will Drive Market Growth

発行 Decision Resources, Inc.
出版日 2006年08月 商品コード 44124
ページ情報 英文 21 Pages
価格
こちらの商品の販売は終了いたしました。

当商品の販売は、2011年12月21日を持ちまして終了しました。

原文目次

Abstract

Sleep disorders affect more than 200 million people worldwide. It is generally accepted that insufficient sleep contributes significantly to automobile accidents and fatalities, work-related injuries, mood depression, and, in general, impaired health. Nevertheless, all sleep disorders are significantly undertreated. This level of unmet need presents a significant market opportunity, and sleep disorders increasingly attract the attention of pharmaceutical companies. Additionally, the imminent patent expiration of the blockbuster agent zolpidem (Sanofi-Aventis's Ambien) has attracted the attention of generics manufacturers. Consequently, the sleep disorders market is likely to experience great change over the next ten years. In this report, we focus on the four sleep disorders thought to have major significance for physical and mental health: insomnia, narcolepsy, restless legs syndrome (RLS), and sleep apnea. We examine their etiology and prevalence, current and emerging therapies, the state of the current market, and the outlook for the sleep disorders market in the United States, Europe, and Japan during the period 2005-2015.

Table of Contents

  • Introduction
  • Overview of Insomnia
  • Etiology and Prevalence
  • Current Therapies
  • Benzodiazepines
  • Non-Benzodiazepines
  • Melatonin Antagonists
  • Narcolepsy
  • Etiology and Prevalence
  • Current Treatments
  • Restless Legs Syndrome
  • Etiology and Prevalence
  • Current Treatments
  • Sleep Apnea
  • Etiology and Prevalence
  • Current Treatments
  • The Sleep Disorders Market
  • Emerging Therapies
  • Insomnia
  • 5-HT2a Antagonists
  • GABA Agonists
  • H1 Antagonists
  • Melatonin Agonists
  • Narcolepsy
  • Restless Legs Syndrome
  • Sleep Apnea
  • Market Outlook
  • United States
  • Europe
  • Japan
  • Table 1 Prevalence of Sleep Disorders, 2005
  • Table 2 Sales of Leading Agents for the Treatment of Sleep Disorders, 2005
  • Table 3 Agents in Development for Treatment of Insomnia, 2006
  • Table 4 Agents in Development for the Treatment of Narcolepsy, Restless Legs Syndrome, and Sleep Apnea
  • Table 5 Forecasted Sales of Drugs for the Treatment of Sleep Disorders in the Three Major-Market Regions, 2010 and 2015
Back to Top